A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- NA · SINGLE GROUP · OTHER · NONE
- Evidence population
- Human clinical study registration
- Participants
- 50
- Population
- ALL · 70 Years to 85 Years
- Duration
- 2013-08-01 to 2017-08-01
- Intervention
- bevacizumab, carboplatin and paclitaxel
- Comparator
- Not reported
- Outcomes measured
- Rate of grade 3-4 neutropenia defined according to National Cancer Institute Common Terminology Criteria version 4.0 (N…; Plasma VEGF — participants will be followed for the duration of the study, around 3 years; Objective response and Stable disease according to RECIST — participants will be followed for the duration of the study…; progression-free survival and overall survival — participants will be followed for the duration of the study, around 3…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.
